Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

139 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
HbA1c, fasting and 2 h plasma glucose in current, ex- and never-smokers: a meta-analysis.
Soulimane S, Simon D, Herman WH, Lange C, Lee CM, Colagiuri S, Shaw JE, Zimmet PZ, Magliano D, Ferreira SR, Dong Y, Zhang L, Jorgensen T, Tuomilehto J, Mohan V, Christensen DL, Kaduka L, Dekker JM, Nijpels G, Stehouwer CD, Lantieri O, Fujimoto WY, Leonetti DL, McNeely MJ, Borch-Johnsen K, Boyko EJ, Vistisen D, Balkau B; DETECT-2 Study Group; DESIR Study Group. Soulimane S, et al. Among authors: vistisen d. Diabetologia. 2014 Jan;57(1):30-9. doi: 10.1007/s00125-013-3058-y. Epub 2013 Sep 25. Diabetologia. 2014. PMID: 24065153 Free PMC article.
Sotagliflozin, a dual sodium-glucose co-transporter-1 and sodium-glucose co-transporter-2 inhibitor, reduces the risk of cardiovascular and kidney disease, as assessed by the Steno T1 Risk Engine in adults with type 1 diabetes.
Stougaard EB, Rossing P, Vistisen D, Banks P, Girard M, Davies MJ, Persson F. Stougaard EB, et al. Among authors: vistisen d. Diabetes Obes Metab. 2023 Jul;25(7):1874-1882. doi: 10.1111/dom.15047. Epub 2023 Mar 20. Diabetes Obes Metab. 2023. PMID: 36872068 Clinical Trial.
Empagliflozin cardiovascular and renal effectiveness and safety compared to dipeptidyl peptidase-4 inhibitors across 11 countries in Europe and Asia: Results from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study.
Karasik A, Lanzinger S, Chia-Hui Tan E, Yabe D, Kim DJ, Sheu WH, Melzer-Cohen C, Holl RW, Ha KH, Khunti K, Zaccardi F, Subramanian A, Nirantharakumar K, Nyström T, Niskanen L, Linnemann Jensen M, Hoti F, Klement R, Déruaz-Luyet A, Kyaw MH, Koeneman L, Vistisen D, Carstensen B, Halvorsen S, Langslet G, Fazeli Farsani S, Patorno E, Núñez J; EMPRISE Europe and Asia Study Group. Karasik A, et al. Among authors: vistisen d. Diabetes Metab. 2023 Mar;49(2):101418. doi: 10.1016/j.diabet.2022.101418. Epub 2023 Jan 3. Diabetes Metab. 2023. PMID: 36608816 Free article.
Association of general health and lifestyle factors with the salivary microbiota - Lessons learned from the ADDITION-PRO cohort.
Poulsen CS, Nygaard N, Constancias F, Stankevic E, Kern T, Witte DR, Vistisen D, Grarup N, Pedersen OB, Belstrøm D, Hansen T. Poulsen CS, et al. Among authors: vistisen d. Front Cell Infect Microbiol. 2022 Nov 16;12:1055117. doi: 10.3389/fcimb.2022.1055117. eCollection 2022. Front Cell Infect Microbiol. 2022. PMID: 36467723 Free PMC article.
There really is an epidemic of type 2 diabetes.
Colagiuri S, Borch-Johnsen K, Glümer C, Vistisen D. Colagiuri S, et al. Among authors: vistisen d. Diabetologia. 2005 Aug;48(8):1459-63. doi: 10.1007/s00125-005-1843-y. Epub 2005 Jul 9. Diabetologia. 2005. PMID: 16007413 Review. No abstract available.
139 results